Insulin-like growth factor binding proteins as glucoregulators

Area of Science:

• Endocrinology
• Metabolic Regulation
• Molecular Biology

Background:

• Circulating insulin-like growth factors (IGFs) possess hypoglycemic potential.
• This activity is primarily inhibited by sequestration within a ternary complex (IGF, IGF-binding protein-3 [IGFBP-3], and acid-labile subunit [ALS]).
• Less than 1% of IGFs are free, but this fraction may significantly contribute to insulin-like activity.

Purpose of the Study:

• To investigate the role of the IGF ternary complex in regulating blood glucose.
• To understand the mechanisms underlying hypoglycemia in IGF-II secreting tumors.
• To explore the involvement of IGFBP-2 and IGFBP-1 in glucose homeostasis.

Main Methods:

• Analysis of IGF, IGFBP-3, ALS, IGFBP-2, and IGFBP-1 levels in relation to blood glucose.
• Observational studies in patients with IGF-II secreting tumors.
• Assessment of treatment effects (corticosteroids, growth hormone) on hypoglycemia and complex formation.

Main Results:

• Impaired ternary complex formation in IGF-II secreting tumors leads to hypoglycemia.
• Treatment with corticosteroids or growth hormone improves hypoglycemia by enhancing complex formation.
• Blood glucose levels inversely correlate with IGFBP-2 and positively with ALS levels.
• IGFBP-1 exhibits acute regulation, suggesting a role as a glucose counterregulator.

Conclusions:

• The IGF ternary complex is crucial for preventing hypoglycemia.
• IGFBP-2 may facilitate IGF transport, while IGFBP-1 acts as a glucose counterregulator.
• Dysregulation of the IGF complex contributes to pathological hypoglycemia.